Analyst Thomas Wei weighs in: "Mirati has two small-molecule oncology drugs that target niche, but potentially lucrative populations. MGCD265 inhibits MET, AXL, and VEGF, and we like the company’s strategy to target a niche of lung cancer patients with MET/AXL mutations/alterations (8-10% of NSCLC). We also see a high probability that Phase 3 asset mocetinostat will have positive data in MDS on a response rate endpoint."

For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.